|
1
|
Sulzer D and Surmeier DJ: Neuronal
vulnerability, pathogenesis, and Parkinson's disease. Mov Disord.
28:715–724. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shukla V, Mishra SK and Pant HC: Oxidative
stress in neurodegeneration. Adv Pharmacol Sci.
2011:5726342011.PubMed/NCBI
|
|
3
|
Kim GH, Kim JE, Rhie SJ and Yoon S: The
role of oxidative stress in neurodegenerative diseases. Exp
Neurobiol. 24:325–340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jenner P: Oxidative stress in Parkinson's
disease. Ann Neurol. 53(Suppl 3): S26–S38. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoritaka A, Hattori N, Uchida K, Tanaka M,
Stadtman ER and Mizuno Y: Immunohistochemical detection of
4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl
Acad Sci USA. 93:2696–2701. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Floor E and Wetzel MG: Increased protein
oxidation in human substantia nigra pars compacta in comparison
with basal ganglia and prefrontal cortex measured with an improved
dinitrophenyl-hydrazine assay. J Neurochem. 70:268–275. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alam ZI, Jenner A, Daniel SE, Lees AJ,
Cairns N, Marsden CD, Jenner P and Halliwell B: Oxidative DNA
damage in the parkinsonian brain: An apparent selective increase in
8-hydroxyguanine levels in substantia nigra. J Neurochem.
69:1196–1203. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Isobe C, Abe T and Terayama Y: Levels of
reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine
in the cerebrospinal fluid of patients with living Parkinson's
disease demonstrate that mitochondrial oxidative damage and/or
oxidative DNA damage contributes to the neurodegenerative process.
Neurosci Lett. 469:159–163. 2010. View Article : Google Scholar
|
|
9
|
Callio J, Oury TD and Chu CT: Manganese
superoxide dismutase protects against 6-hydroxydopamine injury in
mouse brains. J Biol Chem. 280:18536–18542. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Perier C, Bové J, Vila M and Przedborski
S: The rotenone model of Parkinson's disease. Trends Neurosci.
26:345–346. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burns RS, Chiueh CC, Markey SP, Ebert MH,
Jacobowitz DM and Kopin IJ: A primate model of parkinsonism:
Selective destruction of dopaminergic neurons in the pars compacta
of the substantia nigra by
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci
USA. 80:4546–4550. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bhandary B, Marahatta A, Kim HR and Chae
HJ: An involvement of oxidative stress in endoplasmic reticulum
stress and its associated diseases. Int J Mol Sci. 14:434–456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Federico A, Cardaioli E, Da Pozzo P,
Formichi P, Gallus GN and Radi E: Mitochondria, oxidative stress
and neurodegeneration. J Neurol Sci. 322:254–262. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sanders LH and Greenamyre JT: Oxidative
damage to macromolecules in human Parkinson disease and the
rotenone model. Free Radic Biol Med. 62:111–120. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peterson LJ and Flood PM: Oxidative stress
and microglial cells in Parkinson's disease. Mediators Inflamm.
2012:4012642012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fischer R and Maier O: Interrelation of
oxidative stress and inflammation in neurodegenerative disease:
Role of TNF. Oxid Med Cell Longev. 2015:6108132015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Andreyev AY, Kushnareva YE and Starkov AA:
Mitochondrial metabolism of reactive oxygen species. Biochemistry
(Mosc). 70:200–214. 2005. View Article : Google Scholar
|
|
18
|
Cadenas E and Davies KJ: Mitochondrial
free radical generation, oxidative stress, and aging. Free Radic
Biol Med. 29:222–230. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rush JD and Koppenol WH: Oxidizing
intermediates in the reaction of ferrous EDTA with hydrogen
peroxide. Reactions with organic molecules and ferrocytochrome c. J
Biol Chem. 261:6730–6733. 1986.PubMed/NCBI
|
|
20
|
Gutteridge JM: Superoxide-dependent
formation of hydroxyl radicals from ferric-complexes and hydrogen
peroxide: An evaluation of fourteen iron chelators. Free Radic Res
Commun. 9:119–125. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Subramaniam SR and Chesselet MF:
Mitochondrial dysfunction and oxidative stress in Parkinson's
disease. Prog Neurobiol. 106–107:17–32. 2013. View Article : Google Scholar
|
|
22
|
Langston JW, Ballard P, Tetrud JW and
Irwin I: Chronic Parkinsonism in humans due to a product of
meperidine-analog synthesis. Science. 219:979–980. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiba K, Trevor A and Castagnoli N Jr:
Metabolism of the neurotoxic tertiary amine, MPTP, by brain
monoamine oxidase. Biochem Biophys Res Commun. 120:574–578. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Javitch JA, D'Amato RJ, Strittmatter SM
and Snyder SH: Parkinsonism-inducing neurotoxin,
N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: Uptake of the met
abolite N-methyl-4-phenylpyridine by dopamine neurons explains
selective toxicity. Proc Natl Acad Sci USA. 82:2173–2177. 1985.
View Article : Google Scholar
|
|
25
|
Schapira AH, Cooper JM, Dexter D, Clark
JB, Jenner P and Marsden CD: Mitochondrial complex I deficiency in
Parkinson's disease. J Neurochem. 54:823–827. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hattori N, Tanaka M, Ozawa T and Mizuno Y:
Immunohistochemical studies on complexes I, II, III, and IV of
mitochondria in Parkinson's disease. Ann Neurol. 30:563–571. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mizuno Y, Ohta S, Tanaka M, Takamiya S,
Suzuki K, Sato T, Oya H, Ozawa T and Kagawa Y: Deficiencies in
complex I subunits of the respiratory chain in Parkinson's disease.
Biochem Biophys Res Commun. 163:1450–1455. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Parker WD Jr, Parks JK and Swerdlow RH:
Complex I deficiency in Parkinson's disease frontal cortex. Brain
Res. 1189:215–218. 2008. View Article : Google Scholar
|
|
29
|
Krige D, Carroll MT, Cooper JM, Marsden CD
and Schapira AH; The Royal Kings and Queens Parkinson Disease
Research Group: Platelet mitochondrial function in Parkinson's
disease. Ann Neurol. 32:782–788. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Haas RH, Nasirian F, Nakano K, Ward D, Pay
M, Hill R and Shults CW: Low platelet mitochondrial complex I and
complex II/III activity in early untreated Parkinson's disease. Ann
Neurol. 37:714–722. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mytilineou C, Werner P, Molinari S, Di
Rocco A, Cohen G and Yahr MD: Impaired oxidative decarboxylation of
pyruvate in fibroblasts from patients with Parkinson's disease. J
Neural Transm Park Dis Dement Sect. 8:223–228. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Blin O, Desnuelle C, Rascol O, Borg M,
Peyro Saint Paul H, Azulay JP, Billé F, Figarella D, Coulom F,
Pellissier JF, et al: Mitochondrial respiratory failure in skeletal
muscle from patients with Parkinson's disease and multiple system
atrophy. J Neurol Sci. 125:95–101. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoshino H, Nakagawa-Hattori Y, Kondo T and
Mizuno Y: Mitochondrial complex I and II activities of lymphocytes
and platelets in Parkinson's disease. J Neural Transm Park Dis
Dement Sect. 4:27–34. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wen Y, Li W, Poteet EC, Xie L, Tan C, Yan
LJ, Ju X, Liu R, Qian H, Marvin MA, et al: Alternative
mitochondrial electron transfer as a novel strategy for
neuroprotection. J Biol Chem. 286:16504–16515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kudin AP, Debska-Vielhaber G and Kunz WS:
Characterization of superoxide production sites in isolated rat
brain and skeletal muscle mitochondria. Biomed Pharmacother.
59:163–168. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kudin AP, Bimpong-Buta NY, Vielhaber S,
Elger CE and Kunz WS: Characterization of superoxide-producing
sites in isolated brain mitochondria. J Biol Chem. 279:4127–4135.
2004. View Article : Google Scholar
|
|
37
|
Kussmaul L and Hirst J: The mechanism of
superoxide production by NADH:ubiquinone oxidoreductase (complex I)
from bovine heart mitochondria. Proc Natl Acad Sci USA.
103:7607–7612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Morán M, Moreno-Lastres D, Marín-Buera L,
Arenas J, Martín MA and Ugalde C: Mitochondrial respiratory chain
dysfunction: Implications in neurodegeneration. Free Radic Biol
Med. 53:595–609. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dias V, Junn E and Mouradian MM: The role
of oxidative stress in Parkinson's disease. J Parkinsons Dis.
3:461–491. 2013.PubMed/NCBI
|
|
40
|
Morató L, Bertini E, Verrigni D, Ardissone
A, Ruiz M, Ferrer I, Uziel G and Pujol A: Mitochondrial dysfunction
in central nervous system white matter disorders. Glia.
62:1878–1894. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sian-Hülsmann J, Mandel S, Youdim MB and
Riederer P: The relevance of iron in the pathogenesis of
Parkinson's disease. J Neurochem. 118:939–957. 2011. View Article : Google Scholar
|
|
42
|
Kosta P, Argyropoulou MI, Markoula S and
Konitsiotis S: MRI evaluation of the basal ganglia size and iron
content in patients with Parkinson's disease. J Neurol. 253:26–32.
2006. View Article : Google Scholar
|
|
43
|
Sziráki I, Mohanakumar KP, Rauhala P, Kim
HG, Yeh KJ and Chiueh CC: Manganese: A transition metal protects
nigrostriatal neurons from oxidative stress in the iron-induced
animal model of parkinsonism. Neuroscience. 85:1101–1111. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lan J and Jiang DH: Desferrioxamine and
vitamin E protect against iron and MPTP-induced neurodegeneration
in mice. J Neural Transm Vienna. 104:469–481. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ruipérez V, Darios F and Davletov B:
Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res.
49:420–428. 2010. View Article : Google Scholar
|
|
46
|
Dexter DT, Carter CJ, Wells FR, Javoy-Agid
F, Agid Y, Lees A, Jenner P and Marsden CD: Basal lipid
peroxidation in substantia nigra is increased in Parkinson's
disease. J Neurochem. 52:381–389. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dexter DT, Holley AE, Flitter WD, Slater
TF, Wells FR, Daniel SE, Lees AJ, Jenner P and Marsden CD:
Increased levels of lipid hydroperoxides in the parkinsonian
substantia nigra: An HPLC and ESR study. Mov Disord. 9:92–97. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Montine KS, Quinn JF, Zhang J, Fessel JP,
Roberts LJ II, Morrow JD and Montine TJ: Isoprostanes and related
products of lipid peroxidation in neurodegenerative diseases. Chem
Phys Lipids. 128:117–124. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu W, Kato M, Akhand AA, Hayakawa A,
Suzuki H, Miyata T, Kurokawa K, Hotta Y, Ishikawa N and Nakashima
I: 4-hydroxynonenal induces a cellular redox status-related
activation of the caspase cascade for apoptotic cell death. J Cell
Sci. 113:635–641. 2000.PubMed/NCBI
|
|
50
|
Schmidt H, Grune T, Müller R, Siems WG and
Wauer RR: Increased levels of lipid peroxidation products
malondialdehyde and 4-hydroxynonenal after perinatal hypoxia.
Pediatr Res. 40:15–20. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Starkov AA: The role of mitochondria in
reactive oxygen species metabolism and signaling. Ann NY Acad Sci.
1147:37–52. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Murphy MP: How mitochondria produce
reactive oxygen species. Biochem J. 417:1–13. 2009. View Article : Google Scholar
|
|
53
|
Camara AK, Lesnefsky EJ and Stowe DF:
Potential therapeutic benefits of strategies directed to
mitochondria. Antioxid Redox Signal. 13:279–347. 2010. View Article : Google Scholar :
|
|
54
|
Wallace DC: A mitochondrial paradigm of
metabolic and degenerative diseases, aging, and cancer: A dawn for
evolutionary medicine. Annu Rev Genet. 39:359–407. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Levy RJ and Deutschman CS: Deficient
mitochondrial biogenesis in critical illness: Cause, effect, or
epiphenomenon. Crit Care. 11:1582007. View
Article : Google Scholar
|
|
56
|
Kraytsberg Y, Kudryavtseva E, McKee AC,
Geula C, Kowall NW and Khrapko K: Mitochondrial DNA deletions are
abundant and cause functional impairment in aged human substantia
nigra neurons. Nat Genet. 38:518–520. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bender A, Krishnan KJ, Morris CM, Taylor
GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock
T, et al: High levels of mitochondrial DNA deletions in substantia
nigra neurons in aging and Parkinson disease. Nat Genet.
38:515–517. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
58
|
Elstner M, Müller SK, Leidolt L, Laub C,
Krieg L, Schlaudraff F, Liss B, Morris C, Turnbull DM, Masliah E,
et al: Neuromelanin, neurotransmitter status and brainstem location
determine the differential vulnerability of catecholaminergic
neurons to mitochondrial DNA deletions. Mol Brain. 4:432011.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ekstrand MI, Terzioglu M, Galter D, Zhu S,
Hofstetter C, Lindqvist E, Thams S, Bergstrand A, Hansson FS,
Trifunovic A, et al: Progressive parkinsonism in mice with
respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci
USA. 104:1325–1330. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tanner CM, Kamel F, Ross GW, Hoppin JA,
Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR,
et al: Rotenone, paraquat, and Parkinson's disease. Environ Health
Perspect. 119:866–872. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Takeuchi A, Kim B and Matsuoka S: The
destiny of Ca(2+) released by mitochondria. J Physiol Sci.
65:11–24. 2015. View Article : Google Scholar
|
|
62
|
Jo H, Noma A and Matsuoka S:
Calcium-mediated coupling between mitochondrial substrate
dehydrogenation and cardiac workload in single guinea-pig
ventricular myocytes. J Mol Cell Cardiol. 40:394–404. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Satrústegui J, Pardo B and Del Arco A:
Mitochondrial transporters as novel targets for intracellular
calcium signaling. Physiol Rev. 87:29–67. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kirichok Y, Krapivinsky G and Clapham DE:
The mitochondrial calcium uniporter is a highly selective ion
channel. Nature. 427:360–364. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Alderton WK, Cooper CE and Knowles RG:
Nitric oxide synthases: Structure, function and inhibition. Biochem
J. 357:593–615. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jekabsone A, Ivanoviene L, Brown GC and
Borutaite V: Nitric oxide and calcium together inactivate
mitochondrial complex I and induce cytochrome c release. J Mol Cell
Cardiol. 35:803–809. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gandhi S, Wood-Kaczmar A, Yao Z,
Plun-Favreau H, Deas E, Klupsch K, Downward J, Latchman DS, Tabrizi
SJ, Wood NW, et al: INK1-associated Parkinson's disease is caused
by neuronal vulnerability to calcium-induced cell death. Mol Cell.
33:627–638. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Surmeier DJ, Guzman JN, Sanchez-Padilla J
and Goldberg JA: The origins of oxidant stress in Parkinson's
disease and therapeutic strategies. Antioxid Redox Signal.
14:1289–1301. 2011. View Article : Google Scholar :
|
|
69
|
Muravchick S and Levy RJ: Clinical
implications of mitochondrial dysfunction. Anesthesiology.
105:819–837. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
O'Rourke B: Pathophysiological and
protective roles of mitochondrial ion channels. J Physiol.
529:23–36. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Di Lisa F and Bernardi P: A CaPful of
mechanisms regulating the mitochondrial permeability transition. J
Mol Cell Cardiol. 46:775–780. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Jones SP, Teshima Y, Akao M and Marbán E:
Simvastatin attenuates oxidant-induced mitochondrial dysfunction in
cardiac myocytes. Circ Res. 93:697–699. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Vila M and Przedborski S: Targeting
programmed cell death in neurodegenerative diseases. Nat Rev
Neurosci. 4:365–375. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Perier C, Tieu K, Guégan C, Caspersen C,
Jackson-Lewis V, Carelli V, Martinuzzi A, Hirano M, Przedborski S
and Vila M: Complex I deficiency primes Bax-dependent neuronal
apoptosis through mitochondrial oxidative damage. Proc Natl Acad
Sci USA. 102:19126–19131. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Halestrap AP and Brenner C: The adenine
nucleotide trans-locase: A central component of the mitochondrial
permeability transition pore and key player in cell death. Curr Med
Chem. 10:1507–1525. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Adams JM and Cory S: The Bcl-2 protein
family: Arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Theruvath TP, Snoddy MC, Zhong Z and
Lemasters JJ: Mitochondrial permeability transition in liver
ischemia and reperfusion: Role of c-Jun N-terminal kinase 2.
Transplantation. 85:1500–1504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Theruvath TP, Zhong Z, Pediaditakis P,
Ramshesh VK, Currin RT, Tikunov A, Holmuhamedov E and Lemasters JJ:
Minocycline and N-methyl-4-isoleucine cyclosporin (NIM811) mitigate
storage/reperfusion injury after rat liver transplantation through
suppression of the mitochondrial permeability transition.
Hepatology. 47:236–246. 2008. View Article : Google Scholar
|
|
79
|
Li P, Nijhawan D, Budihardjo I,
Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and
dATP-dependent formation of Apaf-1/caspase-9 complex Initiates an
apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Liu X, Kim CN, Yang J, Jemmerson R and
Wang X: Induction of apoptotic program in cell-free extracts:
Requirement for dATP and cytochrome c. Cell. 86:147–157. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kim GT, Chun YS, Park JW and Kim MS: Role
of apoptosis-inducing factor in myocardial cell death by
ischemia-reperfusion. Biochem Biophys Res Commun. 309:619–624.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Susin SA, Lorenzo HK, Zamzami N, Marzo I,
Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler
M, et al: Molecular characterization of mitochondrial
apoptosis-inducing factor. Nature. 397:441–446. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Candé C, Cecconi F, Dessen P and Kroemer
G: Apoptosis-inducing factor (AIF): Key to the conserved
caspase-independent pathways of cell death? J Cell Sci.
115:4727–4734. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Martin LJ: Biology of mitochondria in
neurodegenerative diseases. Prog Mol Biol Transl Sci. 107:355–415.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Obame FN, Plin-Mercier C, Assaly R, Zini
R, Dubois-Randé JL, Berdeaux A and Morin D: Cardioprotective effect
of morphine and a blocker of glycogen synthase kinase 3 beta,
SB216763 [3-(2,4-dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrro
le-2,5-dione], via inhibition of the mitochondrial permeability
transition pore. J Pharmacol Exp Ther. 326:252–258. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Nishihara M, Miura T, Miki T, Tanno M,
Yano T, Naitoh K, Ohori K, Hotta H, Terashima Y and Shimamoto K:
Modulation of the mitochondrial permeability transition pore
complex In GSK-3beta-mediated myocardial protection. J Mol Cell
Cardiol. 43:564–570. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Jope RS and Johnson GV: The glamour and
gloom of glycogen synthase kinase-3. Trends Biochem Sci. 29:95–102.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kockeritz L, Doble B, Patel S and Woodgett
JR: Glycogen synthase kinase-3 - an overview of an over-achieving
protein kinase. Curr Drug Targets. 7:1377–1388. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET
and Yu Q: Pharmacologic modulation of glycogen synthase
kinase-3beta promotes p53-dependent apoptosis through a direct
Bax-mediated mitochondrial pathway in colorectal cancer cells.
Cancer Res. 65:9012–9020. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Watcharasit P, Bijur GN, Song L, Zhu J,
Chen X and Jope RS: Glycogen synthase kinase-3beta (GSK3beta) binds
to and promotes the actions of p53. J Biol Chem. 278:48872–48879.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Linseman DA, Butts BD, Precht TA, Phelps
RA, Le SS, Laessig TA, Bouchard RJ, Florez-McClure ML and
Heidenreich KA: Glycogen synthase kinase-3beta phosphorylates Bax
and promotes its mitochondrial localization during neuronal
apoptosis. J Neurosci. 24:9993–10002. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
King TD, Clodfelder-Miller B, Barksdale KA
and Bijur GN: Unregulated mitochondrial GSK3beta activity results
in NADH: Ubiquinone oxidoreductase deficiency. Neurotox Res.
14:367–382. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wang W, Yang Y, Ying C, Li W, Ruan H, Zhu
X, You Y, Han Y, Chen R, Wang Y, et al: Inhibition of glycogen
synthase kinase-3beta protects dopaminergic neurons from MPTP
toxicity. Neuropharmacology. 52:1678–1684. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
King TD, Bijur GN and Jope RS: Caspase-3
activation induced by inhibition of mitochondrial complex I is
facilitated by glycogen synthase kinase-3beta and attenuated by
lithium. Brain Res. 919:106–114. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Petit-Paitel A, Brau F, Cazareth J and
Chabry J: Involvement of cytosolic and mitochondrial GSK-3beta in
mitochondrial dysfunction and neuronal cell death of
MPTP/MPP-treated neurons. PLoS One. 4:e54912009. View Article : Google Scholar
|
|
96
|
Youdim MB and Ar raf Z: Prevention of MPTP
(N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic
neurotoxicity in mice by chronic lithium: Involvements of Bcl-2 and
Bax. Neuropharmacology. 46:1130–1140. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Li DW, Liu ZQ, Chen W, Yao M and Li GR:
Association of glycogen synthase kinase-3β with Parkinson's disease
(Review). Mol Med Rep. 9:2043–2050. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Spencer JP, Vafeiadou K, Williams RJ and
Vauzour D: Neuroinflammation: Modulation by flavonoids and
mechanisms of action. Mol Aspects Med. 33:83–97. 2012. View Article : Google Scholar
|
|
99
|
Pimplikar SW: Neuroinflammation in
Alzheimer's disease: From pathogenesis to a therapeutic target. J
Clin Immunol. 34(Suppl 1): S64–S69. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Möller T: Neuroinflammation in
Huntington's disease. J Neural Transm Vienna. 117:1001–1008. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Frohman EM, Racke MK and Raine CS:
Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med.
354:942–955. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Hirsch EC, Vyas S and Hunot S:
Neuroinflammation in Parkinson's disease. Parkinsonism Relat
Disord. 18(Suppl 1): S210–S212. 2012. View Article : Google Scholar
|
|
103
|
Zhang F and Jiang L: Neuroinflammation in
Alzheimer's disease. Neuropsychiatr Dis Treat. 11:243–256. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Block ML, Zecca L and Hong JS:
Microglia-mediated neurotoxicity: Uncovering the molecular
mechanisms. Nat Rev Neurosci. 8:57–69. 2007. View Article : Google Scholar
|
|
105
|
Ceulemans AG, Zgavc T, Kooijman R,
Hachimi-Idrissi S, Sarre S and Michotte Y: The dual role of the
neuroinflammatory response after ischemic stroke: Modulatory
effects of hypothermia. J Neuroinflammation. 7:742010. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Chéret C, Gervais A, Lelli A, Colin C,
Amar L, Ravassard P, Mallet J, Cumano A, Krause KH and Mallat M:
Neurotoxic activation of microglia is promoted by a nox1-dependent
NADPH oxidase. J Neurosci. 28:12039–12051. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
McGeer PL and McGeer EG: Glial reactions
in Parkinson's disease. Mov Disord. 23:474–483. 2008. View Article : Google Scholar
|
|
108
|
Frankola KA, Greig NH, Luo W and Tweedie
D: Targeting TNF-α to elucidate and ameliorate neuroinflammation in
neurodegenerative diseases. CNS Neurol Disord Drug Targets.
10:391–403. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Qian L, Flood PM and Hong JS:
Neuroinflammation is a key player in Parkinson's disease and a
prime target for therapy. J Neural Transm Vienna. 117:971–979.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Hunot S, Dugas N, Faucheux B, Hartmann A,
Tardieu M, Debré P, Agid Y, Dugas B and Hirsch EC:
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces,
in vitro, production of nitric oxide and tumor necrosis
factor-alpha in glial cells. J Neurosci. 19:3440–3447.
1999.PubMed/NCBI
|
|
111
|
Mogi M, Harada M, Narabayashi H, Inagaki
H, Minami M and Nagatsu T: Interleukin (IL)-1 beta, IL-2, IL-4,
IL-6 and transforming growth factor-alpha levels are elevated in
ventricular cerebrospinal fluid in juvenile parkinsonism and
Parkinson's disease. Neurosci Lett. 211:13–16. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Hirsch EC, Breidert T, Rousselet E, Hunot
S, Hartmann A and Michel PP: The role of glial reaction and
inflammation in Parkinson's disease. Ann NY Acad Sci. 991:214–228.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Herrera AJ, Castaño A, Venero JL, Cano J
and Machado A: The single intranigral injection of LPS as a new
model for studying the selective effects of inflammatory reactions
on dopaminergic system. Neurobiol Dis. 7:429–447. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Iravani MM, Leung CC, Sadeghian M, Haddon
CO, Rose S and Jenner P: The acute and the long-term effects of
nigral lipopoly-saccharide administration on dopaminergic
dysfunction and glial cell activation. Eur J Neurosci. 22:317–330.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Iravani MM, Sadeghian M, Leung CC, Jenner
P and Rose S: Lipopolysaccharide-induced nigral inflammation leads
to increased IL-1β tissue content and expression of astrocytic
glial cell line-derived neurotrophic factor. Neurosci Lett.
510:138–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Kohutnicka M, Lewandowska E,
Kurkowska-Jastrzebska I, Członkowski A and Członkowska A:
Microglial and astrocytic involvement in a murine model of
Parkinson's disease induced by
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Immunopharmacology. 39:167–180. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Członkowska A, Kohutnicka M,
Kurkowska-Jastrzebska I and Członkowski A: Microglial reaction in
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced
Parkinson's disease mice model. Neurodegeneration. 5:137–143. 1996.
View Article : Google Scholar
|
|
118
|
Sriram K, Miller DB and O'Callaghan JP:
Minocycline attenuates microglial activation but fails to mitigate
striatal dopaminergic neurotoxicity: Role of tumor necrosis
factor-alpha. J Neurochem. 96:706–718. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Mogi M, Harada M, Riederer P, Narabayashi
H, Fujita K and Nagatsu T: Tumor necrosis factor-alpha (TNF-alpha)
increases both in the brain and in the cerebrospinal fluid from
parkinsonian patients. Neurosci Lett. 165:208–210. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Mir M, Tolosa L, Asensio VJ, Lladó J and
Olmos G: Complementary roles of tumor necrosis factor alpha and
interferon gamma in inducible microglial nitric oxide generation. J
Neuroimmunol. 204:101–109. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Lawson LJ, Perry VH, Dri P and Gordon S:
Heterogeneity in the distribution and morphology of microglia in
the normal adult mouse brain. Neuroscience. 39:151–170. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu
B and Hong JS: Regional difference in susceptibility to
lipopolysac-charide-induced neurotoxicity in the rat brain: Role of
microglia. J Neurosci. 20:6309–6316. 2000.PubMed/NCBI
|
|
123
|
Liberatore GT, Jackson-Lewis V, Vukosavic
S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM and
Przedborski S: Inducible nitric oxide synthase stimulates
dopaminergic neurodegeneration in the MPTP model of Parkinson
disease. Nat Med. 5:1403–1409. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
124
|
Zhang F, Qian L, Flood PM, Shi JS, Hong JS
and Gao HM: Inhibition of IkappaB kinase-beta protects dopamine
neurons against lipopolysaccharide-induced neurotoxicity. J
Pharmacol Exp Ther. 333:822–833. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Lofrumento DD, Nicolardi G, Cianciulli A,
De Nuccio F, La Pesa V, Carofiglio V, Dragone T, Calvello R and
Panaro MA: Neuroprotective effects of resveratrol in an MPTP mouse
model of Parkinson's-like disease: Possible role of SOCS-1 in
reducing pro-inflammatory responses. Innate Immun. 20:249–260.
2014. View Article : Google Scholar
|
|
126
|
Gao HM, Zhou H, Zhang F, Wilson BC, Kam W
and Hong JS: HMGB1 acts on microglia Mac1 to mediate chronic
neuroinflammation that drives progressive neurodegeneration. J
Neurosci. 31:1081–1092. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Gao HM and Hong JS: Why neurodegenerative
diseases are progressive: Uncontrolled inflammation drives disease
progression. Trends Immunol. 29:357–365. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Evans MD, Dizdaroglu M and Cooke MS:
Oxidative DNA damage and disease: Induction, repair and
significance. Mutat Res. 567:1–61. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Hegde ML, Gupta VB, Anitha M, Harikrishna
T, Shankar SK, Muthane U, Subba Rao K and Jagannatha Rao KS:
Studies on genomic DNA topology and stability in brain regions of
Parkinson's disease. Arch Biochem Biophys. 449:143–156. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Maynard S, de Souza-Pinto NC,
Scheibye-Knudsen M and Bohr VA: Mitochondrial base excision repair
assays. Methods. 51:416–425. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Sanders LH, McCoy J, Hu X, Mastroberardino
PG, Dickinson BC, Chang CJ, Chu CT, Van Houten B and Greenamyre JT:
Mitochondrial DNA damage: Molecular marker of vulnerable nigral
neurons in Parkinson's disease. Neurobiol Dis. 70:214–223. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Wilson DM III and Barsky D: The major
human abasic endo-nuclease: Formation, consequences and repair of
abasic lesions in DNA. Mutat Res. 485:283–307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Larsen E, Reite K, Nesse G, Gran C,
Seeberg E and Klungland A: Repair and mutagenesis at oxidized DNA
lesions in the developing brain of wild-type and Ogg1−/−
mice. Oncogene. 25:2425–2432. 2006. View Article : Google Scholar
|
|
134
|
Gencer M, Dasdemir S, Cakmakoglu B,
Cetinkaya Y, Varlibas F, Tireli H, Kucukali CI, Ozkok E and Aydin
M: DNA repair genes in Parkinson's disease. Genet Test Mol
Biomarkers. 16:504–507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Mailand N, Gibbs-Seymour I and
Bekker-Jensen S: Regulation of PCNA-protein interactions for genome
stability. Nat Rev Mol Cell Biol. 14:269–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Moldovan GL, Pfander B and Jentsch S:
PCNA, the maestro of the replication fork. Cell. 129:665–679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Burkovics P, Hajdú I, Szukacsov V, Unk I
and Haracska L: Role of PCNA-dependent stimulation of
3′-phosphodiesterase and 3′-5′ exonuclease activities of human Ape2
in repair of oxidative DNA damage. Nucleic Acids Res. 37:4247–4255.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Amoroso A, Concia L, Maggio C, Raynaud C,
Bergounioux C, Crespan E, Cella R and Maga G: Oxidative DNA damage
bypass in Arabidopsis thaliana requires DNA polymerase λ and
proliferating cell nuclear antigen 2. Plant Cell. 23:806–822. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Li DW, Li GR, Zhang BL, Feng JJ and Zhao
H: Damage to dopaminergic neurons is mediated by proliferating cell
nuclear antigen through the p53 pathway under conditions of
oxidative stress in a cell model of Parkinson's disease. Int J Mol
Med. 37:429–435. 2016. View Article : Google Scholar
|
